# Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome

> **NCT04639960** · NA · TERMINATED · sponsor: **University of Geneva, Switzerland** · enrollment: 16 (actual)

## Conditions studied

- 22q11.2 Deletion Syndrome

## Interventions

- **DRUG:** Risperdal
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04639960
- **Lead sponsor:** University of Geneva, Switzerland
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-29
- **Primary completion:** 2021-05-01
- **Final completion:** 2021-05-01
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Difficulties in recruitment of participants and end of funding
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04639960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04639960, "Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04639960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*